Research analysts at Goldman Sachs Group started coverage on shares of Humana (NYSE:HUM) in a research note issued to investors on Wednesday, January 3rd, Marketbeat reports. The brokerage set a “buy” rating and a $305.00 price target on the insurance provider’s stock. Goldman Sachs Group’s price objective would indicate a potential upside of 13.80% from the stock’s current price.
Several other analysts also recently commented on HUM. JPMorgan Chase & Co. downgraded shares of Humana from an “overweight” rating to a “neutral” rating and set a $253.00 target price for the company. in a research report on Monday, October 9th. ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Royal Bank of Canada reissued a “hold” rating and issued a $245.00 target price on shares of Humana in a research report on Tuesday, October 10th. Cowen reaffirmed an “outperform” rating and set a $275.00 price objective (up from $230.00) on shares of Humana in a report on Wednesday, September 20th. Finally, BMO Capital Markets initiated coverage on shares of Humana in a report on Monday, October 16th. They set an “outperform” rating and a $300.00 price objective for the company. Ten analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $258.90.
Shares of Humana (HUM) opened at $268.02 on Wednesday. Humana has a fifty-two week low of $186.25 and a fifty-two week high of $271.99. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. The company has a market cap of $37,887.92, a P/E ratio of 21.09, a P/E/G ratio of 1.73 and a beta of 0.88.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. During the same quarter in the previous year, the business earned $3.18 earnings per share. The firm’s revenue was down 3.0% compared to the same quarter last year. analysts predict that Humana will post 11.63 earnings per share for the current fiscal year.
Humana declared that its Board of Directors has initiated a stock repurchase plan on Thursday, December 14th that allows the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization allows the insurance provider to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.
In other Humana news, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the sale, the senior vice president now directly owns 11,704 shares in the company, valued at approximately $2,901,304.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the sale, the senior vice president now owns 9,888 shares in the company, valued at $2,432,151.36. The disclosure for this sale can be found here. Insiders sold a total of 10,115 shares of company stock worth $2,501,627 in the last ninety days. Insiders own 0.80% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Humana by 1.6% in the second quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock valued at $2,380,366,000 after purchasing an additional 157,868 shares during the last quarter. FMR LLC raised its holdings in shares of Humana by 29.3% in the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after purchasing an additional 1,479,210 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Humana by 9.7% in the second quarter. Capital Research Global Investors now owns 3,907,333 shares of the insurance provider’s stock valued at $940,182,000 after buying an additional 346,069 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Humana by 1.5% in the second quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock valued at $657,157,000 after buying an additional 39,400 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Humana by 74.1% in the third quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock valued at $664,921,000 after buying an additional 1,161,661 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Humana (HUM) Now Covered by Goldman Sachs Group” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/humana-hum-earns-buy-rating-from-analysts-at-goldman-sachs-group.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.